Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isopropamide iodide + trifluoperazine
- Development stage
- Unknown
- Lead developer
- Thrift Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gastobid is an oral fixed-dose combination tablet containing the long-acting anticholinergic agent isopropamide iodide (5 mg) and the typical phenothiazine antipsychotic trifluoperazine (1 mg). Developed by Thrift Pharmaceuticals, it is indicated for the treatment of functional gastrointestinal disorders, primarily irritable bowel syndrome (IBS), peptic ulcer disease, and indigestion. Isopropamide iodide acts as a muscarinic acetylcholine receptor antagonist, relaxing smooth muscles in the digestive tract to relieve painful spasms, cramps, and hypermotility. Trifluoperazine acts as a dopamine D2 receptor antagonist, providing mild anxiolytic and antiemetic effects to alleviate the emotional tension and anxiety that often trigger or exacerbate gastrointestinal distress.
- Brand names
- Gastobid
- Other names
- isopropamide + trifluoperazineisopropamide + trifluoperazine hydrochlorideisopropamide iodide + trifluoperazineisopropamide iodide + trifluoperazine hydrochloride
02
Targets
HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)CaM (Calmodulin)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on isopropamide iodide + trifluoperazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isopropamide iodide + trifluoperazine.